Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Non-Current Assets (2016 - 2025)

Cytosorbents (CTSO) has disclosed Non-Current Assets for 14 consecutive years, with $24.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 21.69% year-over-year to $24.4 million, compared with a TTM value of $49.8 million through Sep 2025, down 57.55%, and an annual FY2024 reading of $25.8 million, down 6.49% over the prior year.
  • Non-Current Assets was $24.4 million for Q3 2025 at Cytosorbents, down from $25.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $31.5 million in Q2 2024 and bottomed at -$25.4 million in Q1 2025.
  • Average Non-Current Assets over 5 years is $23.5 million, with a median of $27.4 million recorded in 2022.
  • The sharpest move saw Non-Current Assets surged 249.53% in 2022, then plummeted 193.85% in 2025.
  • Year by year, Non-Current Assets stood at $25.2 million in 2021, then rose by 16.86% to $29.5 million in 2022, then decreased by 6.49% to $27.6 million in 2023, then decreased by 6.49% to $25.8 million in 2024, then fell by 5.17% to $24.4 million in 2025.
  • Business Quant data shows Non-Current Assets for CTSO at $24.4 million in Q3 2025, $25.0 million in Q2 2025, and -$25.4 million in Q1 2025.